The Liver Meeting 2021-Tiny Yet Powerful Microbes and Their Potential for Treatment of Liver Diseases

Tiny Yet Powerful Microbes and Their Potential for Treatment of Liver Diseases

Video Transcription

Video Summary

Dr. Bernd Schnabel delivered the 2021 Leon Schiff State of the Art Lecture focusing on the gut microbiota's impact on liver diseases. He discussed the complexities of liver diseases such as alcohol-associated liver disease and non-alcoholic fatty liver disease, highlighting factors like genetic, dietary, and lifestyle influences. Dr. Schnabel emphasized the role of the gut microbiota in disease progression, discussing changes in gut viromes, fungi, and bacteria in patients with fatty liver diseases. He explored the potential of engineered bacteria and bacteriophages as therapeutic interventions. The lecture underscored the importance of personalized microbiome-centered therapies for liver disease treatment. Studies on fecal microbiota transplantation, probiotics, and engineered bacteria were discussed, along with the use of metabolites like short-chain fatty acids and bacteriophages. Dr. Schnabel's lecture shed light on emerging treatment strategies targeting the gut microbiota for liver disease management and highlighted the need for further research in this field.

Keywords

Dr. Bernd Schnabel

2021 Leon Schiff State of the Art Lecture

gut microbiota

liver diseases

alcohol-associated liver disease

non-alcoholic fatty liver disease

personalized microbiome-centered therapies